Browsing Tag

EDP1815

Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of…

Eli Pacheco Mar 26, 2022 0

CAMBRIDGE, Mass., March 26, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally…

Health

Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated…

Eli Pacheco Feb 7, 2022 0

Treatment with EDP1815 led to reduced production of cytokines IL-6, IL-8, and TNF in blood cellsCytokine analysis supports gut-restricted action of EDP1815 to resolve inflammation…

Health

Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing…

Eli Pacheco Jan 17, 2022 0

CAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally…

Health

Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis;…

Eli Pacheco Sep 27, 2021 0

–Clinically and statistically significant improvement in PASI-50 score achieved––EDP1815 safety and tolerability data comparable to placebo in study––EDP1815 advancing towards registration…